SEC ownership of Vaxcyte, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001649094.

Comparable stake leader

FMR LLC

Disclosed value leader

FMR LLC

Comparable rows

50/50

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
FMR LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001649094
Issuer location
San Carlos, CA

Ownership snapshot

Top shareholders of Vaxcyte, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G 13F Lead comparable stake: 14% 13D/G row: FMR LLC Showing 1-8 of 50 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 14%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 5
FMR LLC 14%
RA CAPITAL MANAGEMENT, L.P. 8.9%
T. Rowe Price Investment Manageme... 8.6%
BlackRock, Inc. 7.6%
VANGUARD CAPITAL MANAGEMENT LLC 5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13D/G 13F
Company
14%
$1,209,040,462
20,798,907 shares
+$252,740,288 30 Jun 2026
RA CAPITAL MANAGEMENT, L.P.
13D/G 13F
Company
8.9%
$801,181,488
12,974,599 shares
+$624,169 31 Mar 2026
T. Rowe Price Investment Management, Inc.
13F 13D/G
Company
8.6%
from 13D/G
$704,643,000
12,126,017 shares
31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
7.6%
from 13D/G
$637,572,225
10,971,816 shares
31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13D/G 13F
Vanguard Capital Management · Company
5%
$421,416,800
7,252,053 shares
$0 31 Mar 2026
Janus Henderson Group Ltd.
13F 13D/G
Company
0.1%
from 13D/G
$960,231,221
16,575,875 shares
31 Mar 2026
VANGUARD PORTFOLIO MANAGEMENT LLC
13F
Company
13F
4.3%
$364,904,360
6,279,545 shares
31 Mar 2026
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
3.9%
$326,264,231
5,614,597 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$8,709,258.

Buys
$0
Insiders: 0
Sells
$8,709,258
Insiders: 5
Net
-$8,709,258
Shares: -161,299
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 161,299
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 120,646 $0 $6,570,981 -$6,570,981
3-6 0 19,287 $0 $1,126,414 -$1,126,414
6-9 0 21,366 $0 $1,011,863 -$1,011,863
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 24 reporting-owner rows connected to Vaxcyte, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
24
Largest Forms 3/4/5 holder
Grant Pickering
Net 12M change
-$8,709,258
Latest report
05 Aug 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Grant Pickering CHIEF EXECUTIVE OFFICER, Director $32,799,140 -$3,634,850 -10% Filing P/S 27 Jul 2026
Jeff Fairman VP, Research $22,935,618 Mixed 30 Dec 2022
Andrew Guggenhime President And Cfo $9,293,565 -$1,641,716 -15% Mixed 03 Aug 2026
Jim Wassil Chief Operating Officer $8,521,235 -$1,054,132 -11% Filing P/S 03 Aug 2026
Harpreet S. Dhaliwal Chief Technical Ops Officer $4,221,887 -$1,389,959 -25% Filing P/S 05 Aug 2026
Mikhail Eydelman Svp, Gen Counsel & Corp Sec $3,012,039 Filing P/S 05 Mar 2025
Elvia Cowan SVP, Finance & CAO $1,738,500 -$988,601 -36% Filing P/S 07 Apr 2026
Halley E. Gilbert Director $1,171,058 Mixed 15 Jun 2026
Heath Lukatch Director $1,132,040 Mixed 15 Jun 2026
Peter Hirth Director $1,043,024 Mixed 06 Jun 2024
Carlos Paya V Director $725,270 Mixed 15 Jun 2026
Anne S. Drapeau Director $725,270 Mixed 15 Jun 2026
Teri Loxam Director $725,270 Mixed 15 Jun 2026
Jacks Lee Director $398,402 Mixed 15 Jun 2026
Michael E. Kamarck Director $364,388 Mixed 13 Jun 2023
John Furey Director $308,331 Mixed 15 Jun 2026
Olivier Brandicourt Director $273,058 Mixed 15 Jun 2026
Jane Wright-Mitchell General Counsel $202,438 Mixed 16 Aug 2021
Patrick J. Heron Director Mixed 02 Jun 2021
Paul Sauer SVP Process Dev, Manufacturing Mixed 30 Dec 2022

Recent insider transactions for Vaxcyte, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Harpreet S. Dhaliwal PCVX Common Stock Sale -18.1% $935,068 $55.00 -17,000 76,756 05 Aug 2026 Direct
Harpreet S. Dhaliwal PCVX Common Stock Options Exercise 22.2% 17,000 93,756 05 Aug 2026 Direct
Harpreet S. Dhaliwal PCVX Stock Option (right to buy) Options Exercise -37.8% -17,000 28,000 05 Aug 2026 Direct
Jim Wassil PCVX Common Stock Sale -1.41% $121,195 $53.86 -2,250 157,541 03 Aug 2026 Direct
Jim Wassil PCVX Common Stock Options Exercise 1.43% 2,250 159,791 03 Aug 2026 Direct
Jim Wassil PCVX Stock Option (right to buy) Options Exercise -3.16% -2,250 68,898 03 Aug 2026 Direct
Andrew Guggenhime PCVX Common Stock Sale -8.68% $538,879 $53.89 -10,000 105,176 03 Aug 2026 Direct
Andrew Guggenhime PCVX Common Stock Options Exercise 9.51% 10,000 115,176 03 Aug 2026 Direct
Andrew Guggenhime PCVX Stock Option (right to buy) Options Exercise -4.41% -10,000 216,827 03 Aug 2026 Direct
Grant Pickering PCVX Common Stock Sale -1.48% $111,307 $55.65 -2,000 133,215 27 Jul 2026 By Children's Trust
Grant Pickering PCVX Common Stock Sale -3.45% $901,069 $55.63 -16,198 453,247 27 Jul 2026 Direct
Grant Pickering PCVX Common Stock Options Exercise 3.57% 16,198 469,445 27 Jul 2026 Direct
Grant Pickering PCVX Stock Option (right to buy) Options Exercise -10.6% -16,198 137,000 27 Jul 2026 Direct
John Markels PCVX Stock Option (right to buy) Award 23,029 23,029 16 Jul 2026 Direct
Andrew Guggenhime PCVX Common Stock Sale -8.74% $572,837 $57.28 -10,000 104,395 06 Jul 2026 Direct
Andrew Guggenhime PCVX Common Stock Options Exercise 9.58% 10,000 114,395 06 Jul 2026 Direct
Andrew Guggenhime PCVX Stock Option (right to buy) Options Exercise -4.22% -10,000 226,827 06 Jul 2026 Direct
Jim Wassil PCVX Common Stock Sale -1.42% $126,736 $56.33 -2,250 156,760 01 Jul 2026 Direct
Jim Wassil PCVX Common Stock Options Exercise 0.33% 516 159,010 01 Jul 2026 Direct
Jim Wassil PCVX Stock Option (right to buy) Options Exercise -0.72% -516 71,148 01 Jul 2026 Direct
Grant Pickering PCVX Common Stock Sale -1.47% $110,465 $55.23 -2,000 134,215 26 Jun 2026 By Children's Trust
Grant Pickering PCVX Common Stock Sale -4.68% $1,227,805 $55.21 -22,237 452,466 26 Jun 2026 Direct
Moncef Slaoui PCVX Stock Option (right to buy) Award 26,061 26,061 22 Jun 2026 Direct
Grant Pickering PCVX Common Stock Sale -1.46% $105,000 $52.50 -2,000 135,215 18 Jun 2026 By Children's Trust
Grant Pickering PCVX Common Stock Sale -4.52% $1,179,205 $52.50 -22,461 474,703 18 Jun 2026 Direct
Grant Pickering PCVX Common Stock Options Exercise 0.05% 225 497,164 18 Jun 2026 Direct
Grant Pickering PCVX Stock Option (right to buy) Options Exercise -100% -225 0 18 Jun 2026 Direct
Andrew Guggenhime PCVX Common Stock Sale -8.74% $530,000 $53.00 -10,000 104,395 18 Jun 2026 Direct
Andrew Guggenhime PCVX Common Stock Options Exercise 9.58% 10,000 114,395 18 Jun 2026 Direct
Andrew Guggenhime PCVX Stock Option (right to buy) Options Exercise -4.05% -10,000 236,827 18 Jun 2026 Direct
Carlos Paya V PCVX Common Stock Award 49.3% 2,265 6,856 15 Jun 2026 Direct
Carlos Paya V PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Olivier Brandicourt PCVX Common Stock Award 87.6% 2,194 4,699 15 Jun 2026 Direct
Olivier Brandicourt PCVX Stock Option (right to buy) Award 11,034 11,034 15 Jun 2026 Direct
John Furey PCVX Common Stock Award 74.5% 2,265 5,306 15 Jun 2026 Direct
John Furey PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Jacks Lee PCVX Common Stock Award 49.3% 2,265 6,856 15 Jun 2026 Direct
Jacks Lee PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Halley E. Gilbert PCVX Common Stock Award 22.2% 2,265 12,481 15 Jun 2026 Direct
Halley E. Gilbert PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Teri Loxam PCVX Common Stock Award 22.2% 2,265 12,481 15 Jun 2026 Direct
Teri Loxam PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Anne S. Drapeau PCVX Common Stock Award 22.2% 2,265 12,481 15 Jun 2026 Direct
Anne S. Drapeau PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Heath Lukatch PCVX Common Stock Award 13.2% 2,265 19,481 15 Jun 2026 Direct
Heath Lukatch PCVX Stock Option (right to buy) Award 11,389 11,389 15 Jun 2026 Direct
Jim Wassil PCVX Common Stock Sale -1.4% $111,416 $49.52 -2,250 158,494 01 Jun 2026 Direct
Jim Wassil PCVX Common Stock Sale -1.38% $127,870 $56.83 -2,250 160,744 01 May 2026 Direct
Elvia Cowan PCVX Common Stock Sale -9.38% $180,000 $60.00 -3,000 28,975 07 Apr 2026 Direct
Elvia Cowan PCVX Common Stock Options Exercise 10.4% 3,000 31,975 07 Apr 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .